外科理论与实践

外科理论与实践 >

2023 , Vol. 28 >Issue 02: 91 - 93

DOI: https://doi.org/10.16139/j.1007-9610.2023.02.01

专家论坛

肠道因素对胆石病防治的作用

展开
  • 同济大学附属东方医院胆石病中心，上海 200120
    同济大学医学院胆石病研究所，上海 200331

收稿日期: 2023-01-11

  网络出版日期: 2023-06-06

基金资助

国家自然科学基金(82070654);上海市浦东新区卫生健康委员会临床特色学科建设计划(PWYts2021—06)

收起

Factors related to intestine have a role in prevention and treatment for gallstone disease

Expand
  • Center of Gallbladder Disease, Shanghai East Hospital, Tongji University, Shanghai 200120, China
    Institute of Gallstone Disease, Tongji University School of Medicine, Shanghai 200331, China

Received date: 2023-01-11

  Online published: 2023-06-06

Fold

摘要

胆石病是一种常见外科疾病。肠道相关因素在胆石病发生过程中的作用日益受到重视。影响胆固醇结石形成的主要因素包括胆固醇吸收、胆汁酸浓度、肠道菌群改变等，均与肠道相关。正确认识胆石形成中的肠道因素，有助于胆石病的防治。针对肠道不同靶点的治疗方法，未来或许在胆石病预防和胆囊切除术后治疗中起到重要作用。

关键词： 胆石病; 肠道吸收; 胆固醇; 胆汁酸

本文引用格式

蒋兆彦, 沈惟一, 胡海 . 肠道因素对胆石病防治的作用[J]. 外科理论与实践, 2023 , 28(02) : 91 -93 . DOI: 10.16139/j.1007-9610.2023.02.01

Abstract

Gallstone is a common surgical disease. The factors which related to intestine during the process of gallstone formation have attracted increasing attention. The main factors affecting the formation of cholesterol gallstone including cholesterol absorption, bile acid concentration, gut microbiota changing, are all related to the intestine. A correct understanding of the factors related to intestine during gallstone formation is helpful for the prevention and treatment of gallstone disease. In future, different targets related to intestine may play an important role in both prevention of gallstone disease and post-cholecystectomy management.

Key words： Gallstone disease; Intestinal absorption; Cholesterol; Bile acid

参考文献

[1] 蒋兆彦, 吴健, 韩天权, 等. 胆固醇结石病防治研究的再发展[J]. 外科理论与实践, 2015, 20(2):108-111.
[1] JIANG Z Y, WU J, HAN T Q, et al. Study on prevention and treatment of cholesterol gallstone disease[J]. J Surg Concepts Pract, 2015, 20(2):108-111.
[2] LAMMERT F, GURUSAMY K, KO C W, et al. Gallstones[J]. Nat Rev Dis Primers, 2016, 2:16024.
[3] LUO J, YANG H, SONG B L. Mechanisms and regulation of cholesterol homeostasis[J]. Nat Rev Mol Cell Biol, 2020, 21(4):225-245.
[4] ALTMANN S W, DAVIS H R Jr, ZHU L J, et al. Niemann-Pick C1 1 like 1 protein is critical for intestinal cholesterol absorption[J]. Science, 2004, 303(5661):1201-1204.
[5] LI P S, FU Z Y, ZHANG Y Y, et al. The clathrin adaptor Numb regulates intestinal cholesterol absorption through dynamic interaction with NPC1L1[J]. Nat Med, 2014, 20(1):80-86.
[6] ZHANG Y Y, FU Z Y, WEI J, et al. A LIMA1 variant promotes low plasma LDL cholesterol and decreases intestinal cholesterol absorption[J]. Science, 2018, 360(6393):1087-1092.
[7] KAWASE A, ARAKI Y, UEDA Y, et al. Impact of a high-cholesterol diet on expression levels of Niemann-Pick C1-like 1 and intestinal transporters in rats and mice[J]. Eur J Drug Metab Pharmacokinet, 2016, 41(4):457-463.
[8] MALHOTRA P, SONI V, YAMANASHI Y, et al. Mechanisms of Niemann-Pick type C1 like 1 protein degradation in intestinal epithelial cells[J]. Am J Physiol Cell Physiol, 2019, 316(4):C559-C566.
[9] TICHO A L, MALHOTRA P, DUDEJA P K, et al. Intestinal absorption of bile acids in health and disease[J]. Compr Physiol, 2019, 10(1):21-56.
[10] INAGAKI T, CHOI M, MOSCHETTA A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis[J]. Cell Metab, 2005, 2(4):217-225.
[11] 孙海东, 蒋兆彦. 肠道微生态与胆汁酸代谢研究进展[J]. 生命科学, 2016, 28(11):1405-1409.
[11] SUN H D, JIANG Z Y. Recent progress in gut microbiota and bile acid metabolism[J]. Chin Bull Life Sci, 2016, 28(11):1405-1409.
[12] KEREN N, KONIKOFF F M, PAITAN Y, et al. Interactions between the intestinal microbiota and bile acids in gallstones patients[J]. Environ Microbiol Rep, 2015, 7(6):874-880.
[13] WANG Q, HAO C, YAO W, et al. Intestinal flora imba-lance affects bile acid metabolism and is associated with gallstone formation[J]. BMC Gastroenterol, 2020, 20(1):59.
[14] CHOI S B, LEW L C, YEO S K, et al. Probiotics and the BSH-related cholesterol lowering mechanism: a Jekyll and Hyde scenario[J]. Crit Rev Biotechnol, 2015, 35(3):392-401.
[15] JONES M L, TOMARO-DUCHESNEAU C, MARTONI C J, et al. Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications[J]. Expert Opin Biol Ther, 2013, 13(5):631-642.
[16] FUNABASHI M, GROVE T L, WANG M, et al. A metabolic pathway for bile acid dehydroxylation by the gut microbiome[J]. Nature, 2020, 582(7813):566-570.
[17] HU H, SHAO W, LIU Q, et al. Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretion[J]. Nat Commun, 2022, 13(1):252.
[18] CHEN Y, WENG Z, LIU Q, et al. FMO3 and its metabolite TMAO contribute to the formation of gallstones[J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(10):2576-2585.
[19] WEINGLASS A B, KOHLER M, SCHULTE U, et al. Extracellular loop C of NPC1L1 is important for binding to ezetimibe[J]. Proc Natl Acad Sci U S A, 2008, 105(32):11140-11145.
[20] WANG H H, PORTINCASA P, MENDEZ-SANCHEZ N, et al. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones[J]. Gastroenterology, 2008, 134(7):2101-2110.
[21] SHEN W, WANG Y, SHAO W, et al. Dietary plant sterols prevented cholesterol gallstone formation in mice[J]. Food Funct, 2021, 12(23):11829-11837.
[22] HONG T, ZOU J, JIANG X, et al. Curcumin supplementation ameliorates bile cholesterol supersaturation in hamsters by modulating gut microbiota and cholesterol absorption[J]. Nutrients, 2022, 14(9):1828.
[23] LYE H S, RUSUL G, LIONG M T. Removal of cholesterol by lactobacilli via incorporation and conversion to coprostanol[J]. J Dairy Sci, 2010, 93(4):1383-1392.
[24] STIEHL A, RAEDSCH R, RUDOLPH G, et al. Effect of ursodeoxycholic acid on biliary bile acid and bile lipid composition in gallstone patients[J]. Hepatology, 1984, 4(1):107-111.
[25] WANG D Q, TAZUMA S, COHEN D E, et al. Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstone-susceptible mouse[J]. Am J Physiol Gastrointest Liver Physiol, 2003, 285(3):G494-G502.
Options
文章导航

/

〈 〉